In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.
Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.
The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.
Patient aged 65 years or older
Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4.
Hospitalized in an Acute Medicine/Geriatrics Unit
Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.
Refusal to participate
Patient deprived of liberty by a judicial or administrative decision
Patients aged \>65 years with a diagnosis of acute respiratory infection and hospitalized in acute/geriatric wards
Cohort
Prospective
Respiratory viral infection
Other interventionRespiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.
Proportion of participants with death and/or organ decompensation at Day 180
Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.
Proportion of participants who died
Proportion of participants who died from any cause during follow-up.
Proportion of participants with major organ decompensation
Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation.
Proportion of participants with unplanned hospital readmission
Proportion of participants experiencing an unplanned hospital readmission during follow-up.
Proportion of participants developing a lower respiratory tract infection
Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
